Lead Product(s): TILT-123
Therapeutic Area: Oncology
Highest Development Status: Phase I Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 27, 2020
Under the agreement TILT has granted Biotheus rights for development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China.